Biologics and oral systemic treatment preferences in patients and physicians for moderate-to-severe atopic dermatitis: a discrete choice experiment in the United Kingdom and Germany
Background: As the available treatments for moderate-to-severe atopic dermatitis (AD) expand, understanding patient and physician preferences becomes crucial for informed decision-making.Objective: To quantify patient and physician preferences for biologics and oral systemic AD treatment attributes....
Saved in:
| Main Authors: | , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Taylor & Francis Group
2024-12-01
|
| Series: | Journal of Dermatological Treatment |
| Subjects: | |
| Online Access: | https://www.tandfonline.com/doi/10.1080/09546634.2024.2417966 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1850063666626428928 |
|---|---|
| author | Nicholas Durno Pablo Arija Krystallia Pantiri Marieke Heisen Marco Boeri Josef Paris Katrin Jack Olivier Chambenoit Ramkumar Subramanian Jorge Puelles Elly Stolk Ben van Hout Jonathan I. Silverberg |
| author_facet | Nicholas Durno Pablo Arija Krystallia Pantiri Marieke Heisen Marco Boeri Josef Paris Katrin Jack Olivier Chambenoit Ramkumar Subramanian Jorge Puelles Elly Stolk Ben van Hout Jonathan I. Silverberg |
| author_sort | Nicholas Durno |
| collection | DOAJ |
| description | Background: As the available treatments for moderate-to-severe atopic dermatitis (AD) expand, understanding patient and physician preferences becomes crucial for informed decision-making.Objective: To quantify patient and physician preferences for biologics and oral systemic AD treatment attributes.Materials and methods: We conducted a cross-sectional, online discrete choice experiment (DCE) involving 306 AD patients and 206 physicians throughout the United Kingdom and Germany. Qualitative interviews identified the key attributes for inclusion in the DCE. Each choice task comprised two hypothetical patient profiles. Data were analyzed using a random-parameters logit model.Results: Results indicated a significant emphasis on efficacy, with reducing sleep disturbance and itch ranking first and second among patients, and the reverse for physicians. Time to itch relief was the third most important efficacy attribute for both groups, but relatively more important for patients than for physicians. For both groups, the risk of eye problems was the most important safety concern of those included. Mode of administration was not of great importance compared to efficacy and safety attributes.Conclusions: Our findings suggest patients prioritize sleep disturbance, an attribute not captured in prior preference studies in AD, time to itch relief and itch. These findings emphasize the importance of addressing sleep-related issues, whilst also targeting fast itch control, to enhance patients’ well-being. |
| format | Article |
| id | doaj-art-5d66fdb5e6bf46c5b15857f497f87fb6 |
| institution | DOAJ |
| issn | 0954-6634 1471-1753 |
| language | English |
| publishDate | 2024-12-01 |
| publisher | Taylor & Francis Group |
| record_format | Article |
| series | Journal of Dermatological Treatment |
| spelling | doaj-art-5d66fdb5e6bf46c5b15857f497f87fb62025-08-20T02:49:32ZengTaylor & Francis GroupJournal of Dermatological Treatment0954-66341471-17532024-12-0135110.1080/09546634.2024.2417966Biologics and oral systemic treatment preferences in patients and physicians for moderate-to-severe atopic dermatitis: a discrete choice experiment in the United Kingdom and GermanyNicholas Durno0Pablo Arija1Krystallia Pantiri2Marieke Heisen3Marco Boeri4Josef Paris5Katrin Jack6Olivier Chambenoit7Ramkumar Subramanian8Jorge Puelles9Elly Stolk10Ben van Hout11Jonathan I. Silverberg12Modeling and Meta-Analysis, OPEN Health, United KingdomPatient-Centered Outcomes, OPEN Health, the NetherlandsPatient-Centered Outcomes, OPEN Health, the NetherlandsPatient-Centered Outcomes, OPEN Health, the NetherlandsPatient-Centered Outcomes, OPEN Health, United KingdomModeling and Meta-Analysis, OPEN Health, United KingdomGlobal Access Strategy Head, Galderma, SwitzerlandGlobal Head of Medical Strategy, Immunology and Inflammation, Galderma, SwitzerlandGlobal Head of Market Access and Pricing, Galderma, SwitzerlandGlobal Health Economics and Outcomes Research Head, Galderma, SwitzerlandMeasurement and Valuation of Health at Erasmus School of Health Policy and Management, the NetherlandsChief Scientific Officer, Modeling and Meta-Analysis, OPEN Health, United KingdomDirector of Clinical Research, The George Washington University School of Medicine and Health Sciences, WashingtonDC, USABackground: As the available treatments for moderate-to-severe atopic dermatitis (AD) expand, understanding patient and physician preferences becomes crucial for informed decision-making.Objective: To quantify patient and physician preferences for biologics and oral systemic AD treatment attributes.Materials and methods: We conducted a cross-sectional, online discrete choice experiment (DCE) involving 306 AD patients and 206 physicians throughout the United Kingdom and Germany. Qualitative interviews identified the key attributes for inclusion in the DCE. Each choice task comprised two hypothetical patient profiles. Data were analyzed using a random-parameters logit model.Results: Results indicated a significant emphasis on efficacy, with reducing sleep disturbance and itch ranking first and second among patients, and the reverse for physicians. Time to itch relief was the third most important efficacy attribute for both groups, but relatively more important for patients than for physicians. For both groups, the risk of eye problems was the most important safety concern of those included. Mode of administration was not of great importance compared to efficacy and safety attributes.Conclusions: Our findings suggest patients prioritize sleep disturbance, an attribute not captured in prior preference studies in AD, time to itch relief and itch. These findings emphasize the importance of addressing sleep-related issues, whilst also targeting fast itch control, to enhance patients’ well-being.https://www.tandfonline.com/doi/10.1080/09546634.2024.2417966Atopic dermatitisdiscrete choice experimentpatient and physician preferencesitchsleep disturbance |
| spellingShingle | Nicholas Durno Pablo Arija Krystallia Pantiri Marieke Heisen Marco Boeri Josef Paris Katrin Jack Olivier Chambenoit Ramkumar Subramanian Jorge Puelles Elly Stolk Ben van Hout Jonathan I. Silverberg Biologics and oral systemic treatment preferences in patients and physicians for moderate-to-severe atopic dermatitis: a discrete choice experiment in the United Kingdom and Germany Journal of Dermatological Treatment Atopic dermatitis discrete choice experiment patient and physician preferences itch sleep disturbance |
| title | Biologics and oral systemic treatment preferences in patients and physicians for moderate-to-severe atopic dermatitis: a discrete choice experiment in the United Kingdom and Germany |
| title_full | Biologics and oral systemic treatment preferences in patients and physicians for moderate-to-severe atopic dermatitis: a discrete choice experiment in the United Kingdom and Germany |
| title_fullStr | Biologics and oral systemic treatment preferences in patients and physicians for moderate-to-severe atopic dermatitis: a discrete choice experiment in the United Kingdom and Germany |
| title_full_unstemmed | Biologics and oral systemic treatment preferences in patients and physicians for moderate-to-severe atopic dermatitis: a discrete choice experiment in the United Kingdom and Germany |
| title_short | Biologics and oral systemic treatment preferences in patients and physicians for moderate-to-severe atopic dermatitis: a discrete choice experiment in the United Kingdom and Germany |
| title_sort | biologics and oral systemic treatment preferences in patients and physicians for moderate to severe atopic dermatitis a discrete choice experiment in the united kingdom and germany |
| topic | Atopic dermatitis discrete choice experiment patient and physician preferences itch sleep disturbance |
| url | https://www.tandfonline.com/doi/10.1080/09546634.2024.2417966 |
| work_keys_str_mv | AT nicholasdurno biologicsandoralsystemictreatmentpreferencesinpatientsandphysiciansformoderatetosevereatopicdermatitisadiscretechoiceexperimentintheunitedkingdomandgermany AT pabloarija biologicsandoralsystemictreatmentpreferencesinpatientsandphysiciansformoderatetosevereatopicdermatitisadiscretechoiceexperimentintheunitedkingdomandgermany AT krystalliapantiri biologicsandoralsystemictreatmentpreferencesinpatientsandphysiciansformoderatetosevereatopicdermatitisadiscretechoiceexperimentintheunitedkingdomandgermany AT mariekeheisen biologicsandoralsystemictreatmentpreferencesinpatientsandphysiciansformoderatetosevereatopicdermatitisadiscretechoiceexperimentintheunitedkingdomandgermany AT marcoboeri biologicsandoralsystemictreatmentpreferencesinpatientsandphysiciansformoderatetosevereatopicdermatitisadiscretechoiceexperimentintheunitedkingdomandgermany AT josefparis biologicsandoralsystemictreatmentpreferencesinpatientsandphysiciansformoderatetosevereatopicdermatitisadiscretechoiceexperimentintheunitedkingdomandgermany AT katrinjack biologicsandoralsystemictreatmentpreferencesinpatientsandphysiciansformoderatetosevereatopicdermatitisadiscretechoiceexperimentintheunitedkingdomandgermany AT olivierchambenoit biologicsandoralsystemictreatmentpreferencesinpatientsandphysiciansformoderatetosevereatopicdermatitisadiscretechoiceexperimentintheunitedkingdomandgermany AT ramkumarsubramanian biologicsandoralsystemictreatmentpreferencesinpatientsandphysiciansformoderatetosevereatopicdermatitisadiscretechoiceexperimentintheunitedkingdomandgermany AT jorgepuelles biologicsandoralsystemictreatmentpreferencesinpatientsandphysiciansformoderatetosevereatopicdermatitisadiscretechoiceexperimentintheunitedkingdomandgermany AT ellystolk biologicsandoralsystemictreatmentpreferencesinpatientsandphysiciansformoderatetosevereatopicdermatitisadiscretechoiceexperimentintheunitedkingdomandgermany AT benvanhout biologicsandoralsystemictreatmentpreferencesinpatientsandphysiciansformoderatetosevereatopicdermatitisadiscretechoiceexperimentintheunitedkingdomandgermany AT jonathanisilverberg biologicsandoralsystemictreatmentpreferencesinpatientsandphysiciansformoderatetosevereatopicdermatitisadiscretechoiceexperimentintheunitedkingdomandgermany |